AEV 302
Alternative Names: AEV-302Latest Information Update: 16 Mar 2022
Price :
$50 *
At a glance
- Originator AevisBio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 09 Mar 2022 Early research in Cancer (Metastatic disease) in South Korea (unspecified route) (AevisBio pipeline, March 2022)